PKC plays an important mediated effect in arginine vasopressin induced restoration of vascular responsiveness and calcium sensitization following hemorrhagic shock in rats.
The present study investigated the mediated effect of protein kinase C (PKC) in arginine vasopressin (AVP)-induced restoration of vascular responsiveness and calcium sensitization following hemorrhagic shock. Using both isolated superior mesenteric artery from hemorrhagic shock rats and hypoxia-treated vascular smooth muscle cell (VSMC), we investigated the roles of PKC-alpha, delta and epsilon isoforms in AVP-induced restoration of vascular reactivity and calcium sensitivity. Meanwhile, effects of their specific inhibitors on the activity of myosin light chain phosphatase (MLCP), myosin light chain kinase (MLCK), and the phosphorylation of myosin light chain (MLC(20)) in VSMC were observed. The results indicated that AVP improved the reactivity of superior mesenteric artery and VSMC to norepinephrine and calcium following hemorrhagic shock and hypoxia. PKC-alpha inhibitor and PKC-epsilon inhibitory peptide antagonized these effects of AVP, while PKC-delta inhibitor only partially antagonized these effects of AVP. AVP up-regulated the expression of PKC-alpha and epsilon in the particulate fractions of hypoxia-treated VSMC with the decrease of the activity of MLCP and the increase of the phosphorylation of MLC(20). These effects of AVP were inhibited by PKC-alpha inhibitor and PKC-epsilon inhibitory peptide, but not by the PKC-delta inhibitor. The results suggested that PKC plays an important role in AVP-induced restoration of vascular reactivity and calcium sensitivity following hemorrhagic shock. PKC-alpha and epsilon may be the main isoforms involved in this process and play effect via MLC(20) phosphorylation dependent mechanism, while PKC-delta may be partially involved in AVP action by other mechanisms.
Yang
Guangming
G
State Key Laboratory of Trauma, Burns and Combined Injury, The 2nd Department of Research Institute of Surgery, Daping Hospital, The Third Military Medical University, Chongqing, PR China.
Li
Tao
T
Xu
Jing
J
Liu
Liangming
L
D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology*; D002118:Calcium / Q000494:pharmacology*; D015687:Cell Hypoxia; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D008638:Mesenteric Arteries / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D017538:Mesenteric Artery, Superior / Q000187:drug effects* / Q000503:physiopathology*; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000473:pathology; D018994:Myosin Light Chains / Q000378:metabolism; D009219:Myosin-Light-Chain Kinase / Q000378:metabolism; D043263:Myosin-Light-Chain Phosphatase / Q000037:antagonists & inhibitors / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D020127:Recovery of Function / Q000187:drug effects*; D012771:Shock, Hemorrhagic / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D014661:Vasoconstriction / Q000187:drug effects
D004791:Enzyme Inhibitors; D018994:Myosin Light Chains; D001127:Arginine Vasopressin; D011493:Protein Kinase C; D009219:Myosin-Light-Chain Kinase; D043263:Myosin-Light-Chain Phosphatase; D002118:Calcium